• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=20406486).
  
• Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965).
  
• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965).
  

PubMed=20406486; DOI=10.1186/1479-5876-8-39; PMCID=PMC2876068
Sondergaard J.N., Nazarian R., Wang Q., Guo D.-L., Hsueh T., Mok S., Sazegar H., MacConaill L.E., Barretina J.G., Kehoe S.M., Attar N., von Euw E.M., Zuckerman J.E., Chmielowski B., Comin-Anduix B., Koya R.C., Mischel P.S., Lo R.S., Ribas A.
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
J. Transl. Med. 8:39.1-39.11(2010)

PubMed=20689758; DOI=10.1593/neo.10414; PMCID=PMC2915408
Tap W.D., Gong K.-W., Dering J., Tseng Y., Ginther C., Pauletti G., Glaspy J.A., Essner R., Bollag G., Hirth P., Zhang C., Slamon D.J.
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Neoplasia 12:637-649(2010)

PubMed=22194965; DOI=10.1371/journal.pone.0028973; PMCID=PMC3237573
Atefi M., von Euw E.M., Attar N., Ng C., Chu C., Guo D.-L., Nazarian R., Chmielowski B., Glaspy J.A., Comin-Anduix B., Mischel P.S., Lo R.S., Ribas A.
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
PLoS ONE 6:E28973-E28973(2011)

PubMed=22515704; DOI=10.1186/1476-4598-11-22; PMCID=PMC3444881
von Euw E.M., Atefi M., Attar N., Chu C., Zachariah S., Burgess B.L., Mok S., Ng C., Wong D.J.L., Chmielowski B., Lichter D.I., Koya R.C., McCannel T.A., Izmailova E., Ribas A.
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.
Mol. Cancer 11:22.1-22.9(2012)

PubMed=24735930; DOI=10.1186/1476-4598-13-83; PMCID=PMC4021505
Lassen A., Atefi M., Robert L., Wong D.J.L., Cerniglia M., Comin-Anduix B., Ribas A.
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
Mol. Cancer 13:83.1-83.14(2014)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29229836; DOI=10.1073/pnas.1712064115; PMCID=PMC5748184
Su Y.-P., Wei W., Robert L., Xue M., Tsoi J., Garcia-Diaz A., Homet Moreno B., Kim J., Ng R.H.-Y., Lee J.W., Koya R.C., Comin-Anduix B., Graeber T.G., Ribas A., Heath J.R.
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.
Proc. Natl. Acad. Sci. U.S.A. 114:13679-13684(2017)